Who are PEG-IFNa 2a's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Infergen and ribavirin, low immunogenic interferon-beta-1a, Placebo and peginterferon, Peg-IFN + WB RBV for 24 weeks, Interferon beta-1a (Avonex), D: Peg-interferon alpha-2a & Ribavirin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/peg-ifna-2a.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

PEG-IFNa 2a — Competitive Intelligence Brief

PEG-IFNa 2a (PEG-IFNa 2a) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interferon. Area: Oncology.

phase 3 Interferon IFNAR Oncology Small molecule Live · refreshed every 30 min

Target snapshot

PEG-IFNa 2a (PEG-IFNa 2a) — IRCCS San Raffaele. PEG-IFNa 2a is a pegylated form of interferon alpha-2a, which works by stimulating the body's immune system to fight viral infections and cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
PEG-IFNa 2a TARGET	PEG-IFNa 2a	IRCCS San Raffaele	phase 3	Interferon	IFNAR
Infergen and ribavirin	Infergen and ribavirin	Kadmon Corporation, LLC	marketed	Interferon alpha and nucleoside analog combination	Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase
low immunogenic interferon-beta-1a	low immunogenic interferon-beta-1a	Biogen	marketed	Interferon-beta	Interferon-beta receptor (IFNAR)
Placebo and peginterferon	Placebo and peginterferon	National Taiwan University Hospital	marketed	Interferon alpha (pegylated)	Interferon-alpha receptor (IFNAR)
Peg-IFN + WB RBV for 24 weeks	Peg-IFN + WB RBV for 24 weeks	National Taiwan University Hospital	marketed	Immunomodulator + nucleoside analog antiviral combination	Interferon-alpha receptor (IFNAR); HCV RNA-dependent RNA polymerase
Interferon beta-1a (Avonex)	Interferon beta-1a (Avonex)	Biogen	marketed	Interferon beta	Interferon-beta receptor (IFNAR)
D: Peg-interferon alpha-2a & Ribavirin	D: Peg-interferon alpha-2a & Ribavirin	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interferon class)

EMD Serono · 3 drugs in this class
Cinnagen · 2 drugs in this class
Tanabe Pharma Corporation · 2 drugs in this class
Biogen · 1 drug in this class
Celgene · 1 drug in this class
EMD Serono Research & Development Institute, Inc. · 1 drug in this class
Case Comprehensive Cancer Center · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Human Genome Sciences Inc. · 1 drug in this class
Bayer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PEG-IFNa 2a — Competitive Intelligence Brief. https://druglandscape.com/ci/peg-ifna-2a. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab